Abstract
Abstract not available.
Highlights
FMX103 1.5% demonstrated efficacy over vehicle foam in treating papulopustular rosacea in a pooled population of ~1500 subjects, with effects being observed as early as 4 weeks into treatment
Sub-analyses were performed on the integrated data set to characterize the efficacy of FMX103 1.5% in treating papulopustular rosacea in predefined subgroups of subjects
341 (22.4%) subjects reported a TEAE during the 2 identical double-blind Phase 3 studies
Read more 
Summary
Introduction
Rosacea is a common, chronic, inflammatory cutaneous disorder involving the face that affects approximately 16 million individuals in the United States[1,2].
Methods
Results
Summary
Limitations
Conclusions
Disclosures
Sign-in/Register to view highlights & summary Full Text Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
